In this edition, nivolumab confers durable survival benefit; global economic cost of cancer estimated to exceed $25 trillion; phase 3 trials of pembrolizumab miss primary endpoints, and more.

Read the full coverage here:

Neoadjuvant nivolumab confers durable survival benefit in resectable NSCLC

Global economic cost of cancer estimated to exceed $25 trillion over 30 years

Phase 3 trials of pembrolizumab in prostate, lung cancer miss primary endpoints

Researchers develop AI model to accelerate radiation therapy planning for lung cancer

Asian, Black patients with lung cancer face longer wait times to radiation treatment

References:

Chen S, et al. JAMA Oncol. 2023;doi:10.1001/jamaoncol.2022.7826.

Hosny A, et al. Lancet Digit Health. 2022;doi:10.1016/S2589-7500(22)00129-7.

Press Release

Rekulapelli A, et al. Health Equity. 2022;doi:10.1089/heq.2022.0104

Rosner S, et al. Clin Cancer Res. 2023;doi:10.1158/1078-0432.CCR-22-2994.